Skip to main content

Table 1 Laboratory and treatment characteristics of the study population

From: The atrial uremic cardiomyopathy regression in patients after kidney transplantation – the prospective echocardiographic study

Parameter Before KTx Immediately after KTx 3 months after KTx 6 months after KTx 12 months after KTx 36 months after KTx
0 (n = 42) I (n = 42) II (n = 42) III (n = 42) IV (n = 42) V (n = 42)
Biochemical markers
 Haemoglobin [g/dl] 12,25 (±3,67) 10,8 (±3,03) 13,3 (±3,51) 13,65 (±3,38) 13,35 (±3,19) 14,1 (±3,14)
 Natrium [mmol/l] 139,0 (±2,71) 139,5 (±2,45) 141,0 (±2,21) 143,0 (± 2,49) 141,0 (±2,33) 142,1 (±2,13)
 Potassium [mmol/l] 4,7 (±1,31) 4,75 (±1,22) 4,45 (±1,19) 4,55 (±1,15) 4,4 (±1,25) 4,4 (±1,09)
 Magnesium [mmol/l] 0,99 (±0,28) 0,73 (±0,31) 0,72 (±0,26) 0,80 (±0,34) 0,82 (±0,30) 0,83 (±0,37)
 Calcium [mmol/l] 2,54 (±0,24) 2,42 (±0,27) 2,55 (±0,35) 2,6 (±0,29) 2,6 (±0,41) 2,52 (±0,32)
 Phosphorus [mmol/l] 1,68 (±0,49) 0,78 (±0,35) 0,84 (±0,40) 0,92 (±0,33) 0,94 (0,42) 0,97 (±0,43)
 Ca x P [mg2/dl2] 52,47 (±13,94) 23,40 (±8,22) 26,56 (±7,17) 29,68 (±7,93) 30,32 (±6,84) 30,33 (±7,35)
 Parathormone [pg/ml] 734,3 (±656,8) 169,0 (±132,0) 130,2 (±102,9) 113,2 (±90,2) 108,0 (±101,2) 97,0 (±88,6)
 Creatinine [mg/dl] 6,54 (±2,21) 1,45 (±0,51) 1,41 (±0,54) 1,38 (±0,48) 1,36 (±0,60) 1,32 (±0,44)
 eGRF [ml/min/1,73m2] 10,9 (±7,6) 55,6 (±22,9) 56,9 (±21,2) 57,5 (±18,8) 58,72 (±18,3) 60,4 (±15,3)
 Urea [mmol/l] 9,74 (±5,72) 8,39 (±4,98) 7,86 (±4,73) 7,64 (±4,88) 7,74 (±4,32) 7,74 (±4,91)
 Total protein [g/l] 75,0 (±14,3) 61,5 (±13,5) 69,0 (±13,9) 70,2 (±13,2) 71,0 (±14,1) 73,0 (±12,9)
 Albumin [g/l] 4,6 (±1,13) 3,9 (±1,09) 4,4 (±1011) 4,43 (±1,17) 4,45 (±1,21) 4,47 (±1,08)
 hs-CRP [mg/l] 2,12 (±2,22) 0,76 (±1,20) 0,7 (±0,93) 0,66 (±1,39) 0,84 (±0,95) 0,74 (±1,08)
 Total cholesterol [mg/dl] 219,0 (±67,2) 218,55 (±44,5) 205,0 (±40,6) 195,3 (±45,6) 195,5 (±50,2) 197,0 (±52,8)
 LDL-cholesterol [mg/dl] 131,0 (±44,15) 128,0 (±39,6) 113,3 (±42,9) 102,5 (±42,6) 110,5 (±38,5) 108,0 (±34,2)
 HDL-cholesterol [mg/dl] 66,1 (±24,55) 53,5 (±21,8) 57,0 (±19,8) 58,9 (±22,4) 53,5 (±18,9) 61,0 (±20,6)
 Triglycerides [mg/dl] 214,3 (±67,64) 201,0 (±60,3) 183,3 (±64,7) 164,5 (±58,4) 153,5 (±55,6) 126,0 (±52,7)
 Glucose [mg/dl] 90,77 (±47,19) 85,2 (±50,5) 95,0 (±44,2) 94,6 (±39,9) 92,0 (±29,2) 88,1 (±32,3)
 Troponin T [μg/l] 0,018 (±0,037) 0,022 (±0,011) 0,014 (±0,021) 0,013 (±0,015) 0,016 (±0,021) 0,014 (±0,024)
 Myoglobin [ng/ml] 183,5 (±171,1) 38,2 (±36,7) 47,5 (±44,2) 46,5 (±39,5) 57,0 (±35,8) 63,5 (±32,4)
 Creatine kinase [U/l] 81,1 (±86,2) 25,5 (±22,4) 54,5 (±32,5) 80,0 (±35,3) 87,2 (±29,4) 93,0 (±37,2)
 Creatine kinase myocardial bound [U/l] 17,4 (±8,12) 11,8 (±7,21) 16,8 (±9,59) 15,0 (±10,24 15,2 (±8,46) 14,1 (±9,81)
Drugs other than immunosuppressants
 ACE-inhibitors/sartans [n (%)] 0 (%) 0 0 0 0 0
 Calcium blockers [n (%)] 40 (95,2%) 40 (95,2% 38 (90,4%) 38 (90,4%) 36 (85,7%) 36 (85,7%)
 Beta-blockers [n (%)] 23 (54,8%) 25 (59,5%) 26 (61,9%) 24 (57,1%) 26 (61,9%) 27 (64,2%)
 Alfa-blockers [n (%)] 5 (11,9%) 6 (14,2%) 6 (14,2%) 7 (16,6%) 5 (11,9%) 5 (11,9%)
 Clonidine [n (%)] 31 (73,8%) 31 (73,8%) 30 (71,4%) 26 (61,9%) 24 (57,1%) 20 (47,6%)
 Diuretic [n (%)] 40 (95,2%) 30 (71,4%) 18 (42,8%) 10 (23,8%) 6 (14,2%) 5 (11,9%)
 Fibrats [n (%)] 5 (11,9%) 8 (19,0%) 10 (23,8%) 10 (23,8%) 10 (23,8%) 12 (28,5%)
 Statins [n (%)] 3 (7,1%) 10 (23,8%) 17 (40,4%) 22 (52,3%) 22 (52,3%) 23 (54,7%)
Immunosuppressive drugs
 Cyclosporine [n (%)] 21 (50,0%) 21 (50,0%) 20 (47,6%) 18 (42,9%) 17 (40,5%) 12 (28,6%)
 Tacrolimus [n (%)] 21 (50,0%) 21 (50,0%) 22 (52,4%) 24 (57,1%) 25 (59,5%) 30 (71,4%)
 Mycophenolate mofetil [n (%)] 42 (100%) 42 (100%) 42 (100%) 42 (100%) 42 (100%) 42 (100%)
 Prednisone [n (%)] 42 (100%) 42 (100%) 42 (100%) 42 (100%) 42 (100%) 42 (100%)